https://cogentbio.macb.io/wpfd_file/preclinical-in-vitro-and-in-vivo-characterization-of-a-novel-wild-type-sparing-pi3k%ce%b1-h1047r-mutant-selective-inhibitor/2024-10-03T18:51:29+00:00https://cogentbio.macb.io/wpfd_file/symptom-focused-results-from-summit-part-1-an-ongoing-3-part-multi-center-randomized-double-blind-placebo-controlled-phase-2-clinical-study-of-bezuclastinib-in-adult-patients-with-nonadvanced-sy/2024-10-03T18:51:53+00:00https://cogentbio.macb.io/wpfd_file/peak-part-1-summary-a-phase-3-randomized-open-label-multicenter-clinical-study-of-bezuclastinib-cgt9486-and-sunitinib-combination-versus-sunitinib-in-patients-with-gastrointestinal-stromal-tumors/2024-10-03T21:36:10+00:00https://cogentbio.macb.io/wpfd_file/peak-study-a-phase-3-randomized-open-label-multicenter-clinical-study-of-bezuclastinib-cgt9486-and-sunitinib-combination-versus-sunitinib-in-patients-with-gastrointestinal-stromal-tumors-gist/2024-10-03T21:37:25+00:00https://cogentbio.macb.io/wpfd_file/characterization-of-a-novel-egfr-sparing-erbb2-inhibitor-with-activity-across-activating-mutations-in-systemic-and-cns-tumors/2024-10-03T21:38:35+00:00https://cogentbio.macb.io/wpfd_file/physician-and-patient-perspectives-on-relevant-and-burdensome-symptoms-of-non-advanced-systemic-mastocytosis/2024-10-03T21:39:50+00:00https://cogentbio.macb.io/wpfd_file/initial-results-from-summit-an-ongoing-3-part-multi-center-randomized-double-blind-placebo-controlled-phase-2-clinical-study-of-bezuclastinib-in-adult-patients-with-nonadvancedsystemic-mastocyto/2024-10-03T21:41:18+00:00https://cogentbio.macb.io/wpfd_file/safety-and-efficacy-of-bezuclastinib-cgt9486-a-novel-highly-selective-potent-kit-d816v-tyrosine-kinase-inhibitor-in-patients-with-advanced-systemic-mastocytosis-advsm-results-from-part-1-of-t/2024-10-03T21:42:53+00:00https://cogentbio.macb.io/wpfd_file/initial-results-from-summit-an-ongoing-3-part-multi-center-randomized-double-blind-placebo-controlled-phase-2-clinical-study-of-bezuclastinib-in-adult-patients-with-nonadvanced-systemic-mastocyt/2024-10-03T21:46:39+00:00https://cogentbio.macb.io/wpfd_file/identification-of-a-novel-brain-penetrant-egfr-sparing-erbb2-inhibitor-with-activity-against-oncogenic-erbb2-mutations/2024-10-03T21:48:08+00:00https://cogentbio.macb.io/wpfd_file/peak-study-a-phase-3-randomized-open-label-multicenter-clinical-study-of-bezuclastinib-cgt9486-and-sunitinib-combination-versus-sunitinib-in-patients-with-gastrointestinal-stromal-tumors-gist-2/2024-10-03T21:49:26+00:00https://cogentbio.macb.io/wpfd_file/identification-of-an-fgfr1-sparing-reversible-fgfr2-clinical-development-candidate-with-potency-against-gatekeeper-and-molecular-brake-mutations/2024-10-03T21:50:36+00:00https://cogentbio.macb.io/wpfd_file/safety-pharmacokinetics-pk-and-clinical-activity-of-bezuclastinib-sunitinib-in-previously-treated-gastrointestinal-stromal-tumor-gist-results-from-part-1-of-the-phase-3-peak-study/2024-10-03T21:52:18+00:00https://cogentbio.macb.io/wpfd_file/pre-clinical-characterization-of-a-novel-egfr-sparing-erbb2-inhibitor-with-activity-against-oncogenic-erbb2-mutations/2024-10-03T21:53:21+00:00https://cogentbio.macb.io/wpfd_file/in-vivo-characterization-of-a-selective-fgfr2-inhibitor-with-potency-against-gatekeeper-and-molecular-brake-mutations/2024-10-03T21:54:22+00:00https://cogentbio.macb.io/wpfd_file/qualitative-research-to-understand-the-patient-experience-in-non-advanced-systemic-mastocytosis/2024-10-03T21:55:34+00:00https://cogentbio.macb.io/wpfd_file/summit-a-3-part-phase-2-study-of-bezuclastinib-cgt9486-an-oral-selective-and-potent-kit-d816v-inhibitor-in-adult-patients-with-nonadvanced-systemic-mastocytosis-nonadvsm/2024-10-03T21:56:44+00:00https://cogentbio.macb.io/wpfd_file/preliminary-safety-and-efficacy-from-apex-a-phase-2-study-of-bezuclastinib-cgt9486-a-novel-highly-selective-potent-kit-d816v-tyrosine-kinase-inhibitor-in-adults-with-advanced-systemic-mastocyto/2024-10-03T21:58:41+00:00https://cogentbio.macb.io/wpfd_file/a-phase-3-randomized-open-label-multicenter-clinical-study-of-bezuclastinib-cgt9486-and-sunitinib-versus-sunitinib-in-patients-with-gastrointestinal-stromal-tumors/2024-10-03T22:08:59+00:00https://cogentbio.macb.io/wpfd_file/in-vivo-preclinical-characterization-of-a-novel-fgfr2-selective-inhibitor-with-potency-against-fgfr-activating-mutations/2024-10-03T22:10:26+00:00https://cogentbio.macb.io/wpfd_file/preclinical-characterization-of-a-novel-egfr-sparing-erbb2-inhibitor-with-activity-against-oncogenic-erbb2-mutations/2024-10-03T22:12:07+00:00https://cogentbio.macb.io/wpfd_file/a-phase-2-study-of-bezuclastinib-cgt9486-a-novel-highly-selective-potent-kit-d816v-inhibitor-in-adults-with-advanced-systemic-mastocytosis-apex-methods-baseline-data-and-early-insights/2024-10-03T22:13:21+00:00https://cogentbio.macb.io/wpfd_file/pre-clinical-characterization-of-a-novel-series-of-fgfr2-selective-inhibitors-with-potency-against-clinically-relevant-mutations/2024-10-03T22:14:59+00:00https://cogentbio.macb.io/wpfd_file/bezuclastinib-is-a-differentiated-kit-inhibitor-that-exhibits-unique-selectivity-to-kit-a-loop-mutations-minimal-brain-penetration-and-favorable-pharmacokinetic-properties-in-preclinical-models/2024-10-22T23:56:46+00:00https://cogentbio.macb.io/wpfd_file/preclinical-data-identifies-bezuclastinib-as-a-differentiated-kit-inhibitor-with-unique-selectivity-to-kit-d816v-and-minimal-evidence-of-brain-penetration/2024-10-03T22:18:32+00:00https://cogentbio.macb.io/wpfd_file/ctos-oral-presentation-the-potent-and-selective-kit-inhibitor-plx9486-dosed-in-combination-with-sunitinib-demonstrates-promising-progression-free-survival-pfs-in-patients-with-advanced-gastrointest/2024-10-03T22:22:04+00:00https://cogentbio.macb.io/wpfd_file/asco-a-phase-i-pharmacokinetic-and-pharmacodynamic-study-of-plx9486-alone-and-in-combination-with-the-kit-inhibitors-pexidartinib-pexi-or-sunitinib-in-patients-with-advanced-solid-tumors-and-gastro/2024-10-03T22:23:43+00:00https://cogentbio.macb.io/wpfd_file/ctos-a-phase-i-pharmacokinetic-pk-and-pharmacodynamic-pd-study-of-plx9486-a-novel-kit-inhibitor-with-potent-activity-against-exon-17-18-activation-loop-mutations-in-patients-with-gastrointestina/2024-10-03T22:26:45+00:00https://cogentbio.macb.io/wpfd_file/identification-of-a-pan-krason-inhibitor-with-selectivity-over-h-nras-and-pm-activity-across-prevalent-kras-mutations/2024-10-23T15:21:45+00:00https://cogentbio.macb.io/wpfd_file/preclinical-characterization-of-a-novel-pi3k%ce%b1-h1047r-mutant-selective-inhibitor/2024-10-23T11:06:39+00:00https://cogentbio.macb.io/wpfd_file/apex-part-1-updated-assessment-of-bezuclastinib-cgt9486-a-selective-kit-d816v-tyrosine-kinase-inhibitor-in-patients-with-advanced-systemic-mastocytosis-advsm/2024-12-08T23:49:22+00:00https://cogentbio.macb.io/wpfd_file/updated-efficacy-and-safety-results-of-patients-receiving-selected-100mg-bezuclastinib-dose-and-participating-in-the-open-label-extension-of-summit-a-randomized-double-blind-placebo-controlled-phas/2025-02-27T05:24:18+00:00https://cogentbio.macb.io/wpfd_file/apex-part-2-trial-in-progress-a-phase-2-open-label-clinical-study-of-bezuclastinib-in-adult-patients-with-advanced-systemic-mastocytosis/2024-12-09T17:43:13+00:00https://cogentbio.macb.io/wpfd_file/preclinical-characterization-of-cgt6297-a-novel-pi3k%ce%b1-h1047r-mutant-selective-inhibitor/2024-12-13T16:40:58+00:00https://cogentbio.macb.io/wpfd_file/cgt4255-is-a-brain-penetrant-her2-selective-clinical-development-candidate-with-activity-in-cns-and-subcutaneous-tumors/2024-12-13T16:41:50+00:00https://cogentbio.macb.io/wpfd_file/efficacy-and-safety-results-of-adult-patients-with-nonadvanced-systemic-mastocytosis-receiving-bezuclastinib-100-mg-in-the-ongoing-summit-trial-a-randomized-double-blind-placebo-controlled-phase-2/2025-02-27T13:34:38+00:00https://cogentbio.macb.io/wpfd_file/preclinical-characterization-of-cgt6297-a-novel-pi3k%ce%b1-mutant-selective-inhibitor/2025-04-25T12:47:55+00:00https://cogentbio.macb.io/wpfd_file/identification-of-a-potent-krason-inhibitor-with-selectivity-for-mutant-kras-over-hras-and-nras/2025-04-25T12:47:38+00:00https://cogentbio.macb.io/wpfd_file/the-reversible-and-selective-fgfr2-3-inhibitor-cgt4859-has-superior-target-coverage-of-resistance-mutations-missed-by-leading-fgfr-inhibitors/2025-04-25T12:49:53+00:00https://cogentbio.macb.io/wpfd_file/cgt4255-is-an-egfr-sparing-pan-mutant-her2-clinical-development-candidate-with-potential-best-in-class-brain-penetration/2025-04-25T12:51:24+00:00https://cogentbio.macb.io/wpfd_file/identification-of-cgt1263-a-potent-kras-inhibitor-with-selectivity-for-mutant-kras-over-hras-and-nras/2025-10-24T16:29:19+00:00https://cogentbio.macb.io/wpfd_file/efficacy-and-safety-results-from-the-primary-analysis-of-the-pivotal-summit-trial-bezuclastinib-in-adults-with-non-advanced-systemic-mastocytosis/2025-12-08T02:47:20+00:00https://cogentbio.macb.io/wpfd_file/relationship-between-kit-inhibition-by-bezuclastinib-and-effects-on-disease-burden-in-mouse-models-of-systemic-mastocytosis/2025-12-08T19:08:22+00:00https://cogentbio.macb.io/wpfd_file/preclinical-characterization-of-a-novel-wild-type-sparing-jak2-v617f-mutant-selective-inhibitor/2025-12-08T18:50:04+00:00https://cogentbio.macb.io/wpfd_file/the-effect-of-bezuclastinib-on-the-pathobiology-of-mastocytosis-changes-in-bm-mast-cells-tryptase-and-kit-p-d816v-variant-allele-frequency-from-the-pivotal-summit-trial/2025-12-08T21:39:07+00:00